The updated preliminary data from the iLSTA trial, presented at the 2025 ESMO Gastrointestinal Cancers Congress on July 3, 2025, demonstrated an overall response rate of 60% and an overall disease control rate of 100%. After 4 treatment cycles, 13/20 participants showed a RECIST partial response, and 1 participant exhibited a RECIST complete response. The remaining 6 participants demonstrated stable disease. No participant showed an increase in tumor size. Additionally, 16/20 participants experienced a decrease in CA19-9 levels, with 7 participants showing a greater than90% reduction and 9 participants showing a greater than50% reduction in CA19-9 levels.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LSTA:
- Lisata Therapeutics price target raised to $32 from $20 at Brookline
- Lisata Therapeutics Secures U.S. Patent for Certepetide
- Lisata Therapeutics Reveals Promising Phase 2 Trial Data
- Lisata Therapeutics announces preliminary cohort B results from ASCEND trial
- Strategic Collaboration with GATC Health Boosts Lisata Therapeutics’ Growth Potential